PA-PPG
10.1.2020 17:15:04 CET | Business Wire | Press release
PPG (NYSE:PPG) today announced that it will unveil an array of marketplace-ready coatings designed to help enhance electric-vehicle battery performance, durability, safety and cost during the Advanced Automotive Battery Conference (AABC) Europe, Jan. 12-16, 2020, at RheinMain Congress Center in Wiesbaden, Germany. The company also will introduce its latest battery thermal management innovation, PPG CORATHERM™ thermal gap filler, during a technical presentation on Monday, Jan. 13.
The PPG booth (#109) at AABC Europe will feature a broad range of solutions for battery cell and pack applications, including thermal gap fillers, a cathode binder free of N-Methylpyrrolidone (NMP), dielectric and intumescent coatings, pack sealants and adhesives. In addition, Calum Munro, PPG senior scientist, research and technology, automotive original equipment manufacturer (OEM) coatings, will detail the development and validation of PPG Coratherm thermal gap filler. This cost-effective, marketplace-ready thermal management solution offers outstanding performance and low density. It is available in 1K and 2K forms and can be tailored to the unique requirements of each OEM.
PPG will feature its recent success in developing a cost-effective cathode binder that eliminates the use of the solvent NMP. The marketplace-ready binder helps streamline formulation and application processes, reducing mixing times by up to 90%, and contributes to longer battery cycle life. NMP, which is widely used in electrode manufacturing, has been identified as a reproductive hazard by several global regulatory agencies.
“PPG’s participation in AABC Europe will enable us to highlight our expertise in helping customers enhance battery performance, durability and safety while reducing total system cost,” said Munro. “We also partner with customers to ensure successful, high-volume application of our latest battery coatings solutions.”
PPG is enabling electric-vehicle OEMs and battery and component manufacturers to accelerate the development of automotive and commercial vehicle energy storage solutions. The company’s broad-based materials expertise touches virtually every area of lithium-ion battery design and construction, helping PPG customers boost energy density, extend service life, improve safety, increase manufacturing throughput and reduce cost per kilowatt hour.
AABC Europe is one of the world’s leading events for automotive battery technologies, expected to attract more than 1,000 participants representing OEMs, materials suppliers and research organizations.
EDITOR’S NOTE : For more information on PPG coatings for electric-vehicle batteries and other mobility solutions, visit www.ppgautocoatings.com . For more information on AABC Europe, visit www.advancedautobat.com/europe .
PPG: WE PROTECT AND BEAUTIFY THE WORLD™
At PPG (NYSE:PPG), we work every day to develop and deliver the paints, coatings and specialty materials that our customers have trusted for 135 years. Through dedication and creativity, we solve our customers’ biggest challenges, collaborating closely to find the right path forward. With headquarters in Pittsburgh, we operate and innovate in more than 70 countries and reported net sales of $15.4 billion in 2018. We serve customers in construction, consumer products, industrial and transportation markets and aftermarkets. To learn more, visit www.ppg.com .
We protect and beautify the world is a trademark and the PPG Logo is a registered trademark of PPG Industries Ohio, Inc.
CATEGORY: Automotive OEM
View source version on businesswire.com: https://www.businesswire.com/news/home/20200110005378/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom